Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

医学 危险系数 卡铂 彭布罗利珠单抗 内科学 子宫内膜癌 队列 肿瘤科 安慰剂 化疗 癌症 外科 置信区间 病理 顺铂 替代医学 免疫疗法
作者
Ramez N. Eskander,Michael W. Sill,Lindsey Beffa,Richard G. Moore,Joanie M. Hope,Fernanda Musa,Robert S. Mannel,Mark S. Shahin,Guilherme Cantuaria,Eugenia Girda,Cara Mathews,Juraj Kavecansky,Charles A. Leath,Lilian T. Gien,Emily Hinchcliff,Shashikant Lele,Lisa M. Landrum,Floor Backes,Roisin E. O’Cearbhaill,Tareq Al Baghdadi
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:388 (23): 2159-2170 被引量:735
标识
DOI:10.1056/nejmoa2302312
摘要

BACKGROUND: Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear. METHODS: In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 ratio to receive pembrolizumab or placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks. The patients were stratified into two cohorts according to whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease. Previous adjuvant chemotherapy was permitted if the treatment-free interval was at least 12 months. The primary outcome was progression-free survival in the two cohorts. Interim analyses were scheduled to be triggered after the occurrence of at least 84 events of death or progression in the dMMR cohort and at least 196 events in the pMMR cohort. RESULTS: In the 12-month analysis, Kaplan-Meier estimates of progression-free survival in the dMMR cohort were 74% in the pembrolizumab group and 38% in the placebo group (hazard ratio for progression or death, 0.30; 95% confidence interval [CI], 0.19 to 0.48; P<0.001), a 70% difference in relative risk. In the pMMR cohort, median progression-free survival was 13.1 months with pembrolizumab and 8.7 months with placebo (hazard ratio, 0.54; 95% CI, 0.41 to 0.71; P<0.001). Adverse events were as expected for pembrolizumab and combination chemotherapy. CONCLUSIONS: In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone. (Funded by the National Cancer Institute and others; NRG-GY018 ClinicalTrials.gov number, NCT03914612.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
学术雷锋发布了新的文献求助10
刚刚
刚刚
刚刚
刚刚
PDIF-CN2完成签到,获得积分10
1秒前
千陽发布了新的文献求助10
1秒前
pipizhu发布了新的文献求助10
1秒前
hungry完成签到,获得积分10
1秒前
3秒前
思源的应助被研友_ndvmV8采纳,获得20
3秒前
000完成签到 ,获得积分10
3秒前
我是老大的应助被eee采纳,获得10
4秒前
Levon发布了新的文献求助10
4秒前
CK组发布了新的文献求助10
4秒前
4秒前
哈哈哈发布了新的文献求助10
4秒前
无奈的煎饼完成签到 ,获得积分10
4秒前
null的应助被科研通管家采纳,获得10
4秒前
4秒前
今后的应助被科研通管家采纳,获得10
4秒前
4秒前
null的应助被科研通管家采纳,获得10
4秒前
奋斗瑶发布了新的文献求助10
4秒前
咯咯哒给咯咯哒的求助进行了留言
4秒前
5秒前
Hello的应助被科研通管家采纳,获得10
5秒前
5秒前
null的应助被科研通管家采纳,获得10
5秒前
5秒前
YOU完成签到,获得积分20
5秒前
星辰大海的应助被科研通管家采纳,获得10
5秒前
英姑的应助被hh采纳,获得10
5秒前
初雪的应助被科研通管家采纳,获得10
5秒前
NexusExplorer的应助被baoziya采纳,获得10
5秒前
5秒前
5秒前
祝新竹完成签到,获得积分10
6秒前
小太阳在营业的应助被OK采纳,获得250
6秒前
完美世界的应助被风趣的扬青采纳,获得10
7秒前
传奇3的应助被负责的代亦采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161319
求助须知:如何正确求助?哪些是违规求助? 9556017
关于积分的说明 21731933
捐赠科研通 7751355
什么是DOI,文献DOI怎么找? 3427537
关于科研通互助平台的介绍 2552583
邀请新用户注册赠送积分活动 2471987